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We appreciate Drs. Fortuna and Pollio’s interest in our case
report describing a woman with Parkinson’s disease who
developed burning mouth syndrome (BMS) with carbi-
dopa/levodopa therapy that resolved after its discontinua-
tion and initiation of a dopamine agonist.
The authors bring up an excellent and also contentious
point regarding the semantics of burning mouth syndrome
[1, 2]. We utilize the current diagnostic criteria from the
International Headache Society which classifies primary
BMS under ‘‘Central causes of facial pain’’ [3]. The intent
of reporting our case was not to define the syndrome, but
instead to contribute anecdotal evidence to the hypothesis
that the pathophysiology of BMS is related to dopamine
dysregulation. We believe our case supports this notion
given our patient’s diagnosis of Parkinson’s disease and
apparent accentuation of BMS symptoms with adminis-
tration of carbidopa/levodopa [4–6]. Our speculation is that
carbidopa/levodopa’s central action led to the neurophysi-
ological manifestations of BMS. Beyond superficially dis-
missing our patient’s symptoms as drug induced, the value
in our case is related to deeper consideration of the
underlying pathogenesis of BMS.
Although we agree with the authors that it is quite dif-
ficult to delineate the role of depression and anxiety in
cases of burning mouth syndrome [7], we did not think
these psychiatric factors were of primary relevance in our
case as there was no history of such. As outlined in our
report, her BMS symptoms precisely correlated to carbi-
dopa/levodopa administration.
We appreciate the input of Drs. Fortuna and Pollio and
come to the agreement that it is helpful to look at BMS
from a multidisciplinary perspective. This approach will
only advance our understanding of a disease plaguing
patients who seek care from a variety of specialists.
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